ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
65 announcements with these filters
Aster DM Quality Care Ltd reported its first results as a unified entity following the merger with Quality Care. Management highlights strong momentum driven by high-acuity care and operational synergies across 39 hospitals.
Aster DM Quality Care Limited is acquiring an additional 12% stake in its subsidiary, United Ciigma Institute of Medical Sciences, for ₹40.93 Crore.
Aster DM Quality Care reports strong Q1 FY27 results following a landmark merger, focusing on scale and clinical synergies across India.
Aster DM Quality Care Ltd approved the acquisition of an additional 12% stake in subsidiary United CIIGMA for Rs. 40.93 Crore, plus 18th AGM notice details.
Aster DM Quality Care Ltd reported Q1 FY27 combined proforma revenue of ₹2,597 Crore, up 20% YoY. Operating EBITDA grew 30% YoY to ₹576 Crore.
Aster DM Quality Care Q1 FY27 highlights the merger of Aster and Quality Care, reporting combined proforma revenue of INR 2,597 Cr and robust EBITDA margins.
Aster DM Quality Care Ltd reported revenue from operations of ₹1,311 Cr (+21.6% YoY) and net profit of ₹29.3 Cr (-68.7% YoY) for Q1 FY27.
Aster DM Quality Care Ltd will hold a Board of Directors meeting on August 5, 2026, to approve the company's financial results for the quarter ended June 30, 2026.
CRISIL has assigned 'Crisil AA+/Stable' and 'Crisil A1+' ratings to Aster DM Quality Care Limited's bank facilities totaling ₹860.50 Crore.
Aster DM Healthcare Limited is changing its corporate name to Aster DM Quality Care Limited, effective July 28, 2026.
Aster DM promoters' stake diluted from 40.39% to 24.01% following an equity allotment under a Scheme of Amalgamation. This resulted in a 16.38% stake decrease.
BCP Asia II Topco IV and PACs increased their stake in Aster DM Quality Care from 2.69% to 29.71%. The acquisition followed a court-sanctioned Scheme of Amalgamation.
Aster DM allotted 35,35,51,410 equity shares following its merger with Quality Care India Limited. Total paid-up capital increased to Rs.871.67 Crore.
ICRA upgraded Aster DM Quality Care's long-term rating to [ICRA]AA (Stable) from [ICRA]A+. The rating agency also reaffirmed the short-term rating at [ICRA]A1+.
BCP Asia II Topco IV Pte. Ltd acquired a 27.02% stake in Aster DM Quality Care via amalgamation. Its total holding increased to 29.71% following the scheme.
Aster DM Healthcare updated contact details for its Key Managerial Personnel. This ensures streamlined communication for determining event materiality.
Aster DM Healthcare announced multiple changes to its Board and senior management. These include several new director appointments and executive resignations effective July 1, 2026.
Aster DM Healthcare announced the effective date of its amalgamation with Quality Care India Limited. The merger includes promoter category changes and MoA amendments.
Aster DM Healthcare acquired 3,57,143 OCRPS in associate company Alfaone Medicals. The total acquisition cost was ₹25 Crore.
Aster DM Healthcare’s Board approved the NCLT amalgamation with Quality Care India on 25‑June‑2026. Record date set for 9‑July‑2026; exchange ratio 977:1,000 Aster shares.
Aster DM's subsidiary ADMPL allotted CCPS to investors on a preferential basis. The parent's stake will remain above 75% post-conversion, ensuring continued control.
Aster DM Healthcare announced a major merger with Blackstone-backed Quality Care (QCIL) to create a top-3 Indian hospital chain with 10,623 beds and ₹9,273 Cr proforma revenue.
Aster DM Healthcare reported strong Q4 FY26 performance with proforma revenue growing 18% YoY and EBITDA 25%, driven by volume growth and margin expansion ahead of its merger with Quality Care.
Aster DM delivered 18% YoY revenue growth in Q4FY26 reaching ₹1,182 Cr. Post-merger with QCIL, the combined proforma revenue hit ₹2,361 Cr with a focus on bed capacity expansion and operational efficiencies.
Aster DM Healthcare reported Q4FY26 revenue of ₹1,182 Cr (up 18%) and Operating EBITDA of ₹244 Cr (up 26%). Strategy focuses on merger with QCIL and major bed capacity expansion.
Aster DM Healthcare reported Q4 FY26 proforma revenue of ₹2,361 Crore, up 18% YoY, with operating EBITDA increasing 25% to ₹517 Crore. The merger with Quality Care India Limited (QCIL) received 96.68% shareholder approval. The combined entity's capacity will exceed 10,623 beds, positioning it among India's top three healthcare providers.
Aster DM Quality Care Ltd reported revenue from operations of ₹1,182 Cr (+18.2% YoY) and net profit of ₹153.6 Cr (+79.6% YoY) for Q4 FY26.
Aster DM Healthcare Ltd approved its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Statutory auditors Deloitte Haskins & Sells issued an unmodified opinion. The Board also previously distributed an interim dividend of ₹3 per share during the year.
Aster DM Healthcare Ltd has scheduled a Board of Directors meeting on April 30, 2026. The board will consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Aster DM Healthcare Limited and its subsidiary MIMS completed a 26% stake acquisition in Oyster Green Hybrid Two Private Limited for ₹5.80 Crore. The investment was revised from ₹7 Crore due to lower project costs. The acquisition facilitates a captive 18 MWp solar power plant in Kerala to meet the group's renewable energy requirements.